2020 Multiple System Atrophy (MSA) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Multiple System Atrophy (MSA) pipeline report presents a comprehensive overview of the research and development of Multiple System Atrophy (MSA) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, eight drugs in pre-clinical phase, four drugs in phase 1, two drugs in phase 2 and one drug in Phase 3
As of February 2020, the Multiple System Atrophy (MSA) pipeline remains robust with 17 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Multiple System Atrophy (MSA) treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha-synuclein inhibitors; Monoamine oxidase B inhibitors; myeloperoxidase inhibitor; Protein tyrosine kinase inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Multiple System Atrophy (MSA) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline drugs profiled in the report include- 1ST-104, PBT434, Alpha Synuclein inhibitor for Multiple System Atrophy, BIIB101, verdiperstat (AZD3241), CS10BR05, ATV:alpha-synuclein for MSA, emeramide, Alpha synuclein SMART molecule, IkT-148X, Anle138b, NPT200-11, safinamide , Alpha Synuclein inhibitor for neurodegenerative diseases, SBT-272, UB-312, Alpha-synuclein inhibitors for Neurology
As of February 2020, the Multiple System Atrophy (MSA) pipeline remains robust with 17 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Multiple System Atrophy (MSA) treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha-synuclein inhibitors; Monoamine oxidase B inhibitors; myeloperoxidase inhibitor; Protein tyrosine kinase inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Multiple System Atrophy (MSA) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Multiple System Atrophy (MSA) development
- Multiple System Atrophy (MSA) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Multiple System Atrophy (MSA) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Multiple System Atrophy (MSA) pipeline candidates included
- Business overview and snapshot of all companies involved in Multiple System Atrophy (MSA) pipeline are included
- Latest market and pipeline developments are provided in the report
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline drugs profiled in the report include- 1ST-104, PBT434, Alpha Synuclein inhibitor for Multiple System Atrophy, BIIB101, verdiperstat (AZD3241), CS10BR05, ATV:alpha-synuclein for MSA, emeramide, Alpha synuclein SMART molecule, IkT-148X, Anle138b, NPT200-11, safinamide , Alpha Synuclein inhibitor for neurodegenerative diseases, SBT-272, UB-312, Alpha-synuclein inhibitors for Neurology
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Condition
2.3 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Snapshot, 2020
2.4 Companies investing in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline therapeutics
2.5 Phase wise Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Products
2.7 Route of Administration of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 1st Bio Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Alterity Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Arvinas Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Corestem Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Denali Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 EmeraMed Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 ICB International Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Inhibikase Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Modag GmbH Overview, Contacts and ASD Pipeline Drugs
3.12 Neuropore Therapies Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Newron Pharmaceuticals SpA Overview, Contacts and ASD Pipeline Drugs
3.14 ProMIS Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Stealth BioTherapeutics Corp Overview, Contacts and ASD Pipeline Drugs
3.16 United Neuroscience Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Voyager Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 1ST-104 Drug Details
4.1.1 1ST-104 Current Status
4.1.2 1ST-104 Drug Overview
4.1.3 1ST-104 Mechanism of Action
4.1.4 1ST-104 Licensing/Collaboration Companies
4.1.5 1ST-104 Clinical Trials
4.2 PBT434 Drug Details
4.2.1 PBT434 Current Status
4.2.2 PBT434 Drug Overview
4.2.3 PBT434 Mechanism of Action
4.2.4 PBT434 Licensing/Collaboration Companies
4.2.5 PBT434 Clinical Trials
4.3 Alpha Synuclein inhibitor for Multiple System Atrophy Drug Details
4.3.1 Alpha Synuclein inhibitor for Multiple System Atrophy Current Status
4.3.2 Alpha Synuclein inhibitor for Multiple System Atrophy Drug Overview
4.3.3 Alpha Synuclein inhibitor for Multiple System Atrophy Mechanism of Action
4.3.4 Alpha Synuclein inhibitor for Multiple System Atrophy Licensing/Collaboration Companies
4.3.5 Alpha Synuclein inhibitor for Multiple System Atrophy Clinical Trials
4.4 BIIB101 Drug Details
4.4.1 BIIB101 Current Status
4.4.2 BIIB101 Drug Overview
4.4.3 BIIB101 Mechanism of Action
4.4.4 BIIB101 Licensing/Collaboration Companies
4.4.5 BIIB101 Clinical Trials
4.5 verdiperstat (AZD3241) Drug Details
4.5.1 verdiperstat (AZD3241) Current Status
4.5.2 verdiperstat (AZD3241) Drug Overview
4.5.3 verdiperstat (AZD3241) Mechanism of Action
4.5.4 verdiperstat (AZD3241) Licensing/Collaboration Companies
4.5.5 verdiperstat (AZD3241) Clinical Trials
4.6 CS10BR05 Drug Details
4.6.1 CS10BR05 Current Status
4.6.2 CS10BR05 Drug Overview
4.6.3 CS10BR05 Mechanism of Action
4.6.4 CS10BR05 Licensing/Collaboration Companies
4.6.5 CS10BR05 Clinical Trials
4.7 ATV:alpha-synuclein for MSA Drug Details
4.7.1 ATV:alpha-synuclein for MSA Current Status
4.7.2 ATV:alpha-synuclein for MSA Drug Overview
4.7.3 ATV:alpha-synuclein for MSA Mechanism of Action
4.7.4 ATV:alpha-synuclein for MSA Licensing/Collaboration Companies
4.7.5 ATV:alpha-synuclein for MSA Clinical Trials
4.8 emeramide Drug Details
4.8.1 emeramide Current Status
4.8.2 emeramide Drug Overview
4.8.3 emeramide Mechanism of Action
4.8.4 emeramide Licensing/Collaboration Companies
4.8.5 emeramide Clinical Trials
4.9 Alpha synuclein SMART molecule Drug Details
4.9.1 Alpha synuclein SMART molecule Current Status
4.9.2 Alpha synuclein SMART molecule Drug Overview
4.9.3 Alpha synuclein SMART molecule Mechanism of Action
4.9.4 Alpha synuclein SMART molecule Licensing/Collaboration Companies
4.9.5 Alpha synuclein SMART molecule Clinical Trials
4.10 IkT-148X Drug Details
4.10.1 IkT-148X Current Status
4.10.2 IkT-148X Drug Overview
4.10.3 IkT-148X Mechanism of Action
4.10.4 IkT-148X Licensing/Collaboration Companies
4.10.5 IkT-148X Clinical Trials
4.11 Anle138b Drug Details
4.11.1 Anle138b Current Status
4.11.2 Anle138b Drug Overview
4.11.3 Anle138b Mechanism of Action
4.11.4 Anle138b Licensing/Collaboration Companies
4.11.5 Anle138b Clinical Trials
4.12 NPT200-11 Drug Details
4.12.1 NPT200-11 Current Status
4.12.2 NPT200-11 Drug Overview
4.12.3 NPT200-11 Mechanism of Action
4.12.4 NPT200-11 Licensing/Collaboration Companies
4.12.5 NPT200-11 Clinical Trials
4.13 safinamide Drug Details
4.13.1 safinamide Current Status
4.13.2 safinamide Drug Overview
4.13.3 safinamide Mechanism of Action
4.13.4 safinamide Licensing/Collaboration Companies
4.13.5 safinamide Clinical Trials
4.14 Alpha Synuclein inhibitor for neurodegenerative diseases Drug Details
4.14.1 Alpha Synuclein inhibitor for neurodegenerative diseases Current Status
4.14.2 Alpha Synuclein inhibitor for neurodegenerative diseases Drug Overview
4.14.3 Alpha Synuclein inhibitor for neurodegenerative diseases Mechanism of Action
4.14.4 Alpha Synuclein inhibitor for neurodegenerative diseases Licensing/Collaboration Companies
4.14.5 Alpha Synuclein inhibitor for neurodegenerative diseases Clinical Trials
4.15 SBT-272 Drug Details
4.15.1 SBT-272 Current Status
4.15.2 SBT-272 Drug Overview
4.15.3 SBT-272 Mechanism of Action
4.15.4 SBT-272 Licensing/Collaboration Companies
4.15.5 SBT-272 Clinical Trials
4.16 UB-312 Drug Details
4.16.1 UB-312 Current Status
4.16.2 UB-312 Drug Overview
4.16.3 UB-312 Mechanism of Action
4.16.4 UB-312 Licensing/Collaboration Companies
4.16.5 UB-312 Clinical Trials
4.17 Alpha-synuclein inhibitors for Neurology Drug Details
4.17.1 Alpha-synuclein inhibitors for Neurology Current Status
4.17.2 Alpha-synuclein inhibitors for Neurology Drug Overview
4.17.3 Alpha-synuclein inhibitors for Neurology Mechanism of Action
4.17.4 Alpha-synuclein inhibitors for Neurology Licensing/Collaboration Companies
4.17.5 Alpha-synuclein inhibitors for Neurology Clinical Trials
5. LATEST MULTIPLE SYSTEM ATROPHY (MSA OR SHY-DRAGER SYNDROME OR MULTI-SYSTEM DEGENERATION) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Condition
2.3 Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Snapshot, 2020
2.4 Companies investing in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline therapeutics
2.5 Phase wise Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Products
2.7 Route of Administration of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 1st Bio Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Alterity Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Arvinas Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Corestem Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Denali Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 EmeraMed Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 ICB International Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Inhibikase Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Modag GmbH Overview, Contacts and ASD Pipeline Drugs
3.12 Neuropore Therapies Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Newron Pharmaceuticals SpA Overview, Contacts and ASD Pipeline Drugs
3.14 ProMIS Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.15 Stealth BioTherapeutics Corp Overview, Contacts and ASD Pipeline Drugs
3.16 United Neuroscience Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Voyager Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 1ST-104 Drug Details
4.1.1 1ST-104 Current Status
4.1.2 1ST-104 Drug Overview
4.1.3 1ST-104 Mechanism of Action
4.1.4 1ST-104 Licensing/Collaboration Companies
4.1.5 1ST-104 Clinical Trials
4.2 PBT434 Drug Details
4.2.1 PBT434 Current Status
4.2.2 PBT434 Drug Overview
4.2.3 PBT434 Mechanism of Action
4.2.4 PBT434 Licensing/Collaboration Companies
4.2.5 PBT434 Clinical Trials
4.3 Alpha Synuclein inhibitor for Multiple System Atrophy Drug Details
4.3.1 Alpha Synuclein inhibitor for Multiple System Atrophy Current Status
4.3.2 Alpha Synuclein inhibitor for Multiple System Atrophy Drug Overview
4.3.3 Alpha Synuclein inhibitor for Multiple System Atrophy Mechanism of Action
4.3.4 Alpha Synuclein inhibitor for Multiple System Atrophy Licensing/Collaboration Companies
4.3.5 Alpha Synuclein inhibitor for Multiple System Atrophy Clinical Trials
4.4 BIIB101 Drug Details
4.4.1 BIIB101 Current Status
4.4.2 BIIB101 Drug Overview
4.4.3 BIIB101 Mechanism of Action
4.4.4 BIIB101 Licensing/Collaboration Companies
4.4.5 BIIB101 Clinical Trials
4.5 verdiperstat (AZD3241) Drug Details
4.5.1 verdiperstat (AZD3241) Current Status
4.5.2 verdiperstat (AZD3241) Drug Overview
4.5.3 verdiperstat (AZD3241) Mechanism of Action
4.5.4 verdiperstat (AZD3241) Licensing/Collaboration Companies
4.5.5 verdiperstat (AZD3241) Clinical Trials
4.6 CS10BR05 Drug Details
4.6.1 CS10BR05 Current Status
4.6.2 CS10BR05 Drug Overview
4.6.3 CS10BR05 Mechanism of Action
4.6.4 CS10BR05 Licensing/Collaboration Companies
4.6.5 CS10BR05 Clinical Trials
4.7 ATV:alpha-synuclein for MSA Drug Details
4.7.1 ATV:alpha-synuclein for MSA Current Status
4.7.2 ATV:alpha-synuclein for MSA Drug Overview
4.7.3 ATV:alpha-synuclein for MSA Mechanism of Action
4.7.4 ATV:alpha-synuclein for MSA Licensing/Collaboration Companies
4.7.5 ATV:alpha-synuclein for MSA Clinical Trials
4.8 emeramide Drug Details
4.8.1 emeramide Current Status
4.8.2 emeramide Drug Overview
4.8.3 emeramide Mechanism of Action
4.8.4 emeramide Licensing/Collaboration Companies
4.8.5 emeramide Clinical Trials
4.9 Alpha synuclein SMART molecule Drug Details
4.9.1 Alpha synuclein SMART molecule Current Status
4.9.2 Alpha synuclein SMART molecule Drug Overview
4.9.3 Alpha synuclein SMART molecule Mechanism of Action
4.9.4 Alpha synuclein SMART molecule Licensing/Collaboration Companies
4.9.5 Alpha synuclein SMART molecule Clinical Trials
4.10 IkT-148X Drug Details
4.10.1 IkT-148X Current Status
4.10.2 IkT-148X Drug Overview
4.10.3 IkT-148X Mechanism of Action
4.10.4 IkT-148X Licensing/Collaboration Companies
4.10.5 IkT-148X Clinical Trials
4.11 Anle138b Drug Details
4.11.1 Anle138b Current Status
4.11.2 Anle138b Drug Overview
4.11.3 Anle138b Mechanism of Action
4.11.4 Anle138b Licensing/Collaboration Companies
4.11.5 Anle138b Clinical Trials
4.12 NPT200-11 Drug Details
4.12.1 NPT200-11 Current Status
4.12.2 NPT200-11 Drug Overview
4.12.3 NPT200-11 Mechanism of Action
4.12.4 NPT200-11 Licensing/Collaboration Companies
4.12.5 NPT200-11 Clinical Trials
4.13 safinamide Drug Details
4.13.1 safinamide Current Status
4.13.2 safinamide Drug Overview
4.13.3 safinamide Mechanism of Action
4.13.4 safinamide Licensing/Collaboration Companies
4.13.5 safinamide Clinical Trials
4.14 Alpha Synuclein inhibitor for neurodegenerative diseases Drug Details
4.14.1 Alpha Synuclein inhibitor for neurodegenerative diseases Current Status
4.14.2 Alpha Synuclein inhibitor for neurodegenerative diseases Drug Overview
4.14.3 Alpha Synuclein inhibitor for neurodegenerative diseases Mechanism of Action
4.14.4 Alpha Synuclein inhibitor for neurodegenerative diseases Licensing/Collaboration Companies
4.14.5 Alpha Synuclein inhibitor for neurodegenerative diseases Clinical Trials
4.15 SBT-272 Drug Details
4.15.1 SBT-272 Current Status
4.15.2 SBT-272 Drug Overview
4.15.3 SBT-272 Mechanism of Action
4.15.4 SBT-272 Licensing/Collaboration Companies
4.15.5 SBT-272 Clinical Trials
4.16 UB-312 Drug Details
4.16.1 UB-312 Current Status
4.16.2 UB-312 Drug Overview
4.16.3 UB-312 Mechanism of Action
4.16.4 UB-312 Licensing/Collaboration Companies
4.16.5 UB-312 Clinical Trials
4.17 Alpha-synuclein inhibitors for Neurology Drug Details
4.17.1 Alpha-synuclein inhibitors for Neurology Current Status
4.17.2 Alpha-synuclein inhibitors for Neurology Drug Overview
4.17.3 Alpha-synuclein inhibitors for Neurology Mechanism of Action
4.17.4 Alpha-synuclein inhibitors for Neurology Licensing/Collaboration Companies
4.17.5 Alpha-synuclein inhibitors for Neurology Clinical Trials
5. LATEST MULTIPLE SYSTEM ATROPHY (MSA OR SHY-DRAGER SYNDROME OR MULTI-SYSTEM DEGENERATION) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
